The prevalence of substandard or counterfeit safety products and personal protective equipment (PPE) has become a "very serious" problem in the UK, according to the British Safety Industry Federation (BSIF), and could be putting workers in the pharma industry at risk.
The prevalence of substandard or counterfeit safety products and personal protective equipment (PPE) has become a "very serious" problem in the UK, according to the British Safety Industry Federation (BSIF), and could be putting workers in the pharma industry at risk.
Speaking to Pharmaceutical Technology Europe (PTE), Geoff Hooke, BSIF Secretariat, explained that the BSIF receives numerous reports of substandard equipment that does not perform to the standards being claimed, as well as equipment with falsified CE certificates and counterfeit copies of proprietary products.
"The BSIF has received some 15 reports during the past month of products that are 'unsafe' in some way or do not do what they claim," Hooke said to PTE. "During the same period, we have been advised of more than 20 instances of fraudulent product documentation for PPE, which are regulated products with false certification where original certificates have been over-written with different brand names, notified bodies have been changed and the identity of the manufacturer has been altered."
Although the BSIF does not have any statistics or information on the European market, it believes that the threat is a shared issue in the EU marketplace. Many industries are affected, but workers in the pharma industry are particularly vulnerable. "Counterfeit and illegal products pose a great hazard especially in the pharmaceutical industry where workers may be exposed to dangerous substances," said Hooke. "If a product says that it will protect in certain circumstances and does not, there is the potential for someone to get hurt poor protection can put health and, ultimately, lives at risk."
The companies most at risk, according to the spokesperson, will be smaller companies. "Larger companies will likely have better safety regimes and better checks will be made when purchasing and deploying safety products but smaller companies do not always know what to do, do not necessarily have skilled safety managers and do not know what checks to make when selecting and purchasing PPE," Hooke said to PTE.
To help combat the issue in the UK and assist buyers in finding quality supply sources of safety products, the BSIF has launched its Registered Safety Supplier Scheme. Participants can use the scheme shield if they adhere to a strict set of criteria. Companies that do not comply could lose their registered safety supplier and, possibly, membership of the BSIF.
"The issue of counterfeit and illegal products is growing in the safety industry," David Hall, Chairman of the BSIF, said in a press release. "By joining this initiative we hope to give users of PPE equipment greater re-assurance and send a clear signal to those who sell or produce counterfeit and illegal products that there is a no place for these in the UK market."
Why is the PDA Pharmaceutical Microbiology Conference the Hottest Ticket in the Industry?
October 10th 2024Get a glimpse of the power and popularity behind the PDA Pharmaceutical Microbiology Conference from two planning committee members, Julia Marre, PhD (Associate Director, Scientific and Regulatory Affairs at Pocket Naloxone Corp) and Dawn Watson (Executive Director, Global Micro Quality and Sterility Assurance at Merck). This candid conversation reveals why this industry event is so influential…and always sold out! The speakers discuss what makes the PDA Pharmaceutical Microbiology Conference so vital to industry professionals, as well as how to become a part of this dynamic professional community.
Navigating Annex 1 for Early Phase Sterile Fill Finish in Clinical Supplies
November 21st 2024Stay compliant with Annex 1 for early phase sterile fill finish processes. Discover how to implement robust contamination control strategies, integrate isolator technology, and conduct integrity testing to meet stringent European Union standards. The guide provides a comprehensive look at key elements such as PUPSIT, critical zone controls, and monitoring and training for aseptic processes.
Your Ultimate Guide for CMC Testing Support for Gene and Cell Therapy
November 21st 2024Explore the complexities of gene and cell therapy development with our comprehensive guide to Chemistry, Manufacturing, and Controls (CMC) testing. Learn how our expertise ensures the safety, potency, and quality of advanced therapies, supporting your journey from product development through regulatory approval.